Data Show Pristiq Reduces Symptoms of Major Depressive Disorder

Wyeth Pharmaceuticals reported data from two Phase III clinical studies of Pristiq for the treatment of major depressive disorder.

The studies evaluated Pristiq (desvenlafaxine) at 50 and 100 mg/day and found patients who received the 50-mg/day dose experienced a statistically significant reduction in the symptoms compared with placebo, according to Wyeth.

Wyeth sent the results of the studies to the FDA in August as part of its complete response to the approvable letter it received in January. FDA action is expected during the first quarter of 2008.